24 June 2020 (Wednesday) - Berzosertib
An email from “Oncology Central” – Berzosertib: a new precision medicine which shows promise in advanced tumours by blocking a key DNA repair protein. The ATR inhibitor, either on its own or with chemotherapy, was tested in 40 patients with very advanced tumors. The team established doses at which the drug is safe to use and discovered that berzosertib only caused mild side effects…
Perhaps not something I will use on a daily basis, but when I see this in diagnosis I will be slightly less in the dark than I might have been.
Labels: Oncology Central